Business
Personalis, Inc. Expands Genomics Portfolio Across Disease Areas With Launch of Pharma Research Solutions for Use in Early Drug Discovery and Preclinical Studies
MENLO PARK, Calif.--(BUSINESS WIRE)-- Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of their Pharma
About this update from Personalis, Inc.
[{"type":"text","content":" MENLO PARK, Calif.--(BUSINESS WIRE)--\nPersonalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of their Pharma Research Solutions, the latest expansion of the company’s portfolio of comprehensive genomics assays and analytics. These solutions, which leverage Personalis’ patented ACE Technology, are designed for use in early drug discovery and preclinical studies in oncology, but also other disease areas. These offerings complement Personalis’ comprehensive immunogenomics platform, ImmunoID NeXT™, which is currently used for clinical biomarker and companion diagnostic development in translational research and clinical trials by the company’s pharmaceutical partners.\n\n\n“Our Pharma Research Solutions provide our customers with access to a broad suite of both proprietary and standard assays from targeted DNA and RNA panels through to whole genome and whole exome and transcriptome services. Our expansive sample processing and sequencing capacity, combined with our experience and expertise in executing large-scale projects as part of biopharma oncology clinical trials as well as the VA Million Veterans Program, makes us the ideal partner for pharmaceutical companies aiming to harmonize their genomics strategy across all preclinical and clinical programs,” said John West, CEO of Personalis. “Additionally, we have seen increasing interest amongst our pharma partners in leveraging ImmunoID NeXT and other solutions in areas such as inflammatory disease and other genetic disorders. This represents both the broad applicability of our technology and a potentially large growth opportunity for our business.”\n\n\nThe Pharma Research Solutions integrate Personalis’ ACE Technology to improve sequencing performance in complex, difficult-to-sequence regions of the genome that are insufficiently covered by conventional NGS approaches. The assays and bioinformatics capabilities offered by Personalis’ Pharma Research Solutions can enable the identification of novel drug targets and the generation of deeper insights into drug candidates’ mechanisms of action and associated resistance mechanisms in human and non-human models -- in a cost-effective and highly-scalable manner. These solutions also facilitate the company’s pursuit of new, large-scale population sequencing projects. Every step in the proces...